Epithelial Mesenchymal Transition (EMT), as defined by loss of epithelial characteristics and gaining a more mesenchymal-like phenotype, has been largely reported in vivo. However, the actual occurrence of events defining EMT is rarely fully observed in vivo.
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We aimed to explore the translational landscapes of EMT in breast cancer (BC) with relevance to potential triggering pathways and BC molecular subtypes. Clustering analysis was performed on a well-defined clinically annotated series of invasive non-lobular BC (n = 431) prepared as tissue microarray (TMAs). A large panel of biomarkers including cadherins, TGFb1, PIK3CA, pAkt, cytokeratins, Erb-family members and hormone receptors, has been studied. Differential expression of EMT markers was observed between molecular BC subtypes (Luminal1 and 2, HER2 + , and basal-like (BLBC), where BLBC expressed lower Ecad, higher P-cad, smooth muscle actin and PIK3CA, relative to HER2 + BC that expressed highest levels of N-cad, TGFb1 and PIK3CA. Within luminal tumours subdivisions, expression levels of N-cad, TGFb1, pAkt and PIK3CA differed considerably. N-cad contributed to cluster separation more than E-cad (F = 13.14 and 1.68, respectively). Moreover, E-cad/N-cad switch occurred more frequently in BLBC and HER2 + . Significant differences were observed between these four clusters for breast cancer-specific and disease-free survivals (p < 0.001).
BLBC and HER2 + BC preferentially displayed EMT/cadherin switch than luminal BC, explaining their indigenous tendency for progression. In addition, EMT/cadherin switch programs in BC appear to occur synergistically with TGFb1 and PIK3/Akt pathways activation. These data explain, at translational level, the varied clinical behaviour of BC molecular classes, thus could help developing targeted therapies against EMT-associated pathways. Cell line studies demonstrate that sphingosine kinase 1 (SK1) and extracellular signal regulated kinase 1/2 (ERK-1/2) interact in an oestrogen receptor (ER) dependent manner to influence breast cancer cell growth and migration. A cohort of 304 ER positive breast cancer patients, were utilised to investigate the prognostic significance of SK1, sphingosine 1-phosphate receptors 1, 2 and 3 (S1P 1 , S1P 2 an S1P 3 ) and ERK-1/2 expression. Expression levels of SK1, S1P 1 , S1P 2 and S1P 3 were established by immunohistochemistry. Cytoplasmic and nuclear SK1 expression was associated with shorter time to recurrence on tamoxifen (recurrence time) (p = 0.022 and p = 0.016, respectively) and high membrane S1P 1 expression was also associated with shorter time to recurrence (p = 0.008). High cytoplasmic S1P 1 and S1P 3 expression were associated with shorter disease specific survival (p = 0.036 and p = 0.019). Those patients with tumours that expressed high levels of both cytoplasmic SK1 and ERK-1/2 had significantly shorter recurrence time than those that expressed low levels of cytoplasmic SK1 and cytoplasmic ERK-1/2 (p = 0.00008), with a difference in recurrence time of 10.5 years. Similarly, high cytoplasmic S1P 1 and cytoplasmic ERK-1/2 expression (p = 0.004) and high cytoplasmic S1P 3 expression and cytoplasmic ERK-1/2 expression (p = 0.004), were associated with shorter recurrence time. These results support a model in which the interaction between SK1, S1P 1 and/or S1P 3 and ERK-1/2 might drive breast cancer progression and this therefore warrants further investigation. Kaplan-Meier survival analysis was performed using SPSS.
Histological excision margins were increasingly clear over time 88% (88/93), 91.5% (94/97) and 98% (00/03). The overall local recurrence free survival rate was identical for both earlier periods with 92% at 5 years but improved to 96.1% over 2000/03. 40-56% of all local recurrences were invasive; 13/23 (88/93), 14/26 (94/97), and 8/21 (00/03). Use of tamoxifen within the three cohorts was similar (44-46%) and made no significant difference to rates of local or contralateral recurrence free survival. Significant differences in local recurrence rates by operation type were observed (see Table 1 ).
Conclusion: Local recurrence rates after breast conserving surgery for screen detected DCIS have reduced over time. This is likely to be related to higher rates of non-operative diagnosis, combined with improved histological assessment (grading and 
